BRD4: From molecular understanding to therapeutics development

Area of Science:

• Epigenetics and Molecular Biology
• Drug Discovery and Development

Background:

• Bromodomain-containing protein 4 (BRD4) is a key therapeutic target for anticancer, antiviral, and anti-inflammatory treatments.
• Beyond transcription, BRD4 and its BET family members regulate diverse molecular and biological processes.
• Understanding context-specific regulation by BRD4 is crucial for therapeutic advancements.

Purpose of the Study:

• To review the roles of BRD4 isoforms and posttranslational modifications, particularly phosphorylation, in generating protein diversity.
• To discuss the phospho-switch mechanism controlling BRD4's bromodomain and protein interactions.
• To highlight novel therapeutic strategies targeting BRD4.

Main Methods:

• Literature review focusing on BRD4 function, isoforms, and posttranslational modifications.
• Analysis of the phospho-switch mechanism in BRD4 regulation.
• Examination of emerging therapeutic approaches targeting BRD4.

Main Results:

• Three BRD4 isoforms (BRD4-L, BRD4-S(a), BRD4-S(b)) contribute to functional diversity.
• Phosphorylation acts as a switch, modulating BRD4's bromodomain and interactions with partner proteins.
• Novel inhibitors target phospho-BRD4's intrinsically disordered region (IDR) for specific protein-protein interaction (PPI) network modulation.

Conclusions:

• Protein isoforms and phosphorylation are critical for BRD4's context-specific gene regulation.
• Targeting phospho-BRD4 IDRs offers a strategy for developing therapeutics with reduced off-target effects.
• This research opens new avenues for drug development in oncology and inflammatory diseases.